Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2011

01.07.2011 | Original Paper

Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer

verfasst von: Bai Zhao, Tiemin Sun, Fanjuan Meng, Aibing Qu, Chunling Li, Hui Shen, Yu Jin, Wenxin Li

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lung cancer is one of the most malignant tumors and poses a significant threat to human health. Osteopontin (OPN) is a variably expressed, secreted glycophosphoprotein that mediates the growth and metastases of several carcinoma types. In this study, we aimed to understand the role of OPN in lung cancer cell proliferation and invasiveness.

Methods

Expression of OPN was examined using an immunohistochemical method in paraffin-embedded sections collected from 49 patients with lung cancer. We silenced OPN expression by lentivirus-mediated OPN-specific small interfering RNA (siRNA) and examined the proliferation and invasiveness of OPN-silenced lung cancer cell (A549) through MTT, BrdU, flow cytometry, and Matrigel assay. In addition, we tested the role of individual OPN splice variants in A549 cell growth and invasion by constructing OPN overexpression lentiviruses.

Result

Downregulation of OPN inhibited A549 cell proliferation and in vivo tumor growth, abrogated augmentation of invasion, induced G1-phase cell cycle arrest, and induced cell late apoptosis and necrosis. Moreover, the proliferation and invasiveness was linked to different OPN splice variants, of which OPN-b affected the cell proliferation and OPN-c showed significant correlation with invasion behavior.

Conclusions

Our data suggested that OPN served as a potential biomarker for invasive lung cancer and provided new molecular-targeted therapy for lung cancer based on lentivirus-mediated RNA interference.
Literatur
Zurück zum Zitat Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521PubMed Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521PubMed
Zurück zum Zitat Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457PubMedCrossRef Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457PubMedCrossRef
Zurück zum Zitat Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12:3337–3343PubMedCrossRef Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12:3337–3343PubMedCrossRef
Zurück zum Zitat Campbell TN, Choy FY (2005) RNA interference: past, present and future. Curr Issues Mol Biol 7:1–6PubMed Campbell TN, Choy FY (2005) RNA interference: past, present and future. Curr Issues Mol Biol 7:1–6PubMed
Zurück zum Zitat Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311–323PubMedCrossRef Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311–323PubMedCrossRef
Zurück zum Zitat Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43:225–236PubMedCrossRef Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43:225–236PubMedCrossRef
Zurück zum Zitat Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRef Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRef
Zurück zum Zitat Ehrchen J, Heuer H, Sigmund R, Schafer MK, Bauer K (2001) Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. J Endocrinol 169:87–96PubMedCrossRef Ehrchen J, Heuer H, Sigmund R, Schafer MK, Bauer K (2001) Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. J Endocrinol 169:87–96PubMedCrossRef
Zurück zum Zitat Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS (2010) Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5:1516–1523PubMedCrossRef Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS (2010) Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5:1516–1523PubMedCrossRef
Zurück zum Zitat Inman CK, Shore P (2003) The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684–48689PubMedCrossRef Inman CK, Shore P (2003) The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684–48689PubMedCrossRef
Zurück zum Zitat Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T, Shimada Y (2006) An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 12:1308–1316PubMedCrossRef Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T, Shimada Y (2006) An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 12:1308–1316PubMedCrossRef
Zurück zum Zitat Jessen KA, Liu SY, Tepper CG, Karrim J, McGoldrick ET, Rosner A, Munn RJ, Young LJ, Borowsky AD, Cardiff RD, Gregg JP (2004) Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res 6:157–169CrossRef Jessen KA, Liu SY, Tepper CG, Karrim J, McGoldrick ET, Rosner A, Munn RJ, Young LJ, Borowsky AD, Cardiff RD, Gregg JP (2004) Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res 6:157–169CrossRef
Zurück zum Zitat Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671–1679CrossRef Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671–1679CrossRef
Zurück zum Zitat Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90:986–992PubMed Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90:986–992PubMed
Zurück zum Zitat Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF (2008) Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122:889–897PubMedCrossRef Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF (2008) Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122:889–897PubMedCrossRef
Zurück zum Zitat Nagatomo T, Ohga S, Takada H, Nomura A, Hikino S (2004) Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol 138:47–53PubMedCrossRef Nagatomo T, Ohga S, Takada H, Nomura A, Hikino S (2004) Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol 138:47–53PubMedCrossRef
Zurück zum Zitat Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed
Zurück zum Zitat Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23:123–133PubMedCrossRef Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23:123–133PubMedCrossRef
Zurück zum Zitat Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361–6371PubMedCrossRef Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361–6371PubMedCrossRef
Zurück zum Zitat Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMed Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMed
Zurück zum Zitat Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mamm Gland Biol Neoplasia 6:419–429CrossRef Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mamm Gland Biol Neoplasia 6:419–429CrossRef
Zurück zum Zitat Tuck AB, O’Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121:578–584PubMed Tuck AB, O’Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121:578–584PubMed
Zurück zum Zitat Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 9:127–132CrossRef Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 9:127–132CrossRef
Zurück zum Zitat Wang Y, Yang H, Liu H, Huang J, Song X (2009) Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer 9:174PubMedCrossRef Wang Y, Yang H, Liu H, Huang J, Song X (2009) Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer 9:174PubMedCrossRef
Zurück zum Zitat Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed
Metadaten
Titel
Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer
verfasst von
Bai Zhao
Tiemin Sun
Fanjuan Meng
Aibing Qu
Chunling Li
Hui Shen
Yu Jin
Wenxin Li
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0968-7

Weitere Artikel der Ausgabe 7/2011

Journal of Cancer Research and Clinical Oncology 7/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.